{"ModuleTitle": "Company Description", "CompanyName": "Pluristem Therapeutics, Inc.", "Symbol": "PSTI", "Address": "MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA, 3508409, Israel", "Phone": "972-74-710-7171", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "Middle East", "CompanyDescription": "Pluristem Therapeutics Inc. is a leading developer of placenta-based cell\r\ntherapy product candidates for the treatment of multiple ischemic, inflammatory\r\nand hematologic conditions. Our lead indications are critical limb ischemia, or\r\nCLI, muscle recovery following surgery for hip fracture, and acute radiation\r\nsyndrome, or ARS. Each of these indications is a severe unmet medical need. We\r\nwere incorporated in Nevada in 2001, and have a wholly owned subsidiary in\r\nIsrael called Pluristem Ltd. We operate in one segment and our operations are\r\nfocused on the research, development, clinical trials and manufacturing of cell\r\ntherapeutics and related technologies.\r\n\r\n \r\n\r\nPLX cells are derived from a class of placental cells that are harvested from\r\ndonated placenta at the time of full term healthy delivery of a baby. PLX cell\r\nproducts require no tissue matching prior to administration. They are produced\r\nusing our proprietary three-dimensional expansion technology.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2019%2f09%2f12%2f0001213900-19-017859.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Chen Franco-Yehuda", "title": "Chief Financial Officer, Secretary & Treasurer"}, {"name": "Dan Peres", "title": "Vice President-Clinical & Medical Affairs"}, {"name": "Lior Raviv", "title": "Vice President-Operations & Development"}, {"name": "Liran Shani", "title": "Vice President-Clinical & Medical Affairs"}, {"name": "Yaky Yanay", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}